Thyroglobulin Antibodies as a Prognostic Factor in Papillary Thyroid Carcinoma Patients with Indeterminate Response After Initial Therapy

Abstract

The clinical outcome of papillary thyroid carcinoma (PTC) patients with an indeterminate response after initial therapy is reported to be intermediate, between incomplete and excellent responses. This study evaluated the outcomes of PTC patients with indeterminate response after initial therapy. It was further determined whether the indeterminate findings predicted outcomes more precisely. Patients were further classified into 3 groups based on risk of structural persistence/recurrence: Tg group: detectable thyroglobulin, negative antithyroglobulin antibody, regardless nonspecific imaging findings; TgAb group: positive antithyroglobulin antibody, regardless thyroglobulin levels and nonspecific imaging findings, and Image group: nonspecific findings on neck ultrasonography or faint uptake in the thyroid bed on whole-body scan, undetectable thyroglobulin and negative antithyroglobulin antibody. Sixty-six patients aged 44.1±12.7 years were studied, of whom 58 (87.9%) were females. All patients underwent total thyroidectomy, and 52 patients (78.8%) received radioiodine. After 5.7 years (P25–75 2.6–9.75 years) of follow-up, most patients (89.4%) were reclassified as having an excellent response or remained in the indeterminate response to therapy. Structural recurrence/persistence disease was detected in 7 (10.6%) patients. The persistence/recurrence rate in groups were as follow: Tg, 2.63%; TgAb, 31.25%; Image, 8.3% (p=0.007). The 10-years disease-free survival rate in the TgAb group was significantly reduced (p=0.022). Our results suggest that patients with PTC and indeterminate response due to positive serum antithyroglobulin antibody have more risk of development of structural disease. These findings suggest a more individualized follow-up strategy for patients with an indeterminate response.

Key words

dynamic risk stratification - initial response to therapy - recurrence

Publication History

Received: 26 June 2020

Accepted after revision: 25 July 2020

Article published online:
04 September 2020

• References

• 1 Vaisman F, Tutlle RM. Clinical assessment and risk stratification in differentiated thyroid cancer. Endocrinol Metab Clin North Am 2019; 48: 99-108
• 2 Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid carcinoma: From detection to final follow-up. J Clin Endocrinol Metab 2019; 104: 4087-4100
• 3 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016: (26) 1-133
• 4 Tuttle RM, Tala H, Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20: 1341-1349
• 5 Jeon MJ, Kim WG, Park WR. et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2013; 170: 23-30
• 6 Scheffel RS, Zanella AB, Antunes D. et al. Low recurrence rates in a cohort of differentiated thyroid carcinoma patients: A referral center experience. Thyroid 2015; 25: 883-889
• 7 Pacini F, Basolo F, Bellantone R. et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: Joint statements of six Italian societies. J Endocrinol Invest 2018; 41: 849-876
• 8 Oh HS, Ahn JH, Song E. et al. Individualized follow-up strategy for patients with an indeterminate response to initial therapy for papillary thyroid carcinoma. Thyroid 2019; 29: 209-215
• 9 Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/ Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (8^th ed): What Changed and Why?. Thyroid 2017; 27: 751-756
• 10 Kim WG, Yoon JH, Kim WB. et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 4683-4689
• 11 Xu J, Bergren R, Schneider D. et al. Thyroglobulin antibody resolution after total thyroidectomy for cancer. J Surg Res 2015; 198: 366-370
• 12 Durante C, Tognini S, Montesano T. et al. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid 2014; 24: 1139-1145
• 13 Rosario PW, Carvalho M, Mourão GF, Calsolari M. Comparison of antithyroglobulin antibody concentrations before and after ablation with 131I as a predictor of structural disease in differentiated thyroid carcinoma patients with undetectable basal thyroglobulin and negative neck ultrasonography. Thyroid 2016; 26: 525-531
• 14 Schlumberger M, Hitzel A, Toubert ME. et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007; 92: 2487-2495
• 15 Rosario PW, Mourão GF, Calsolari MR. Definition of the response to initial therapy with radioiodine in patients with differentiated thyroid carcinoma: Basal or stimulated thyroglobulin?. Horm Metab Res 2019; 51: 634-638
• 16 Lamartina L, Montesano T, Trulli F. et al. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: Repeat stimulated thyroglobulin assay to identify disease-free patients. Endocrine 2016; 54: 467-475
• 17 Malandrino P, Tumino D, Russo M. et al. Surveillance of patients with differentiated thyroid cancer and indeterminate response: A longitudinal study on basal thyroglobulin trend. J Endocrinol Invest 2019; 42: 1223-1230
• 18 Lamartina L, Grani G, Biffoni M. et al. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J Clin Endocrinol Metab 2016; 101: 3036-3044
• 19 Robenshtok E, Fish S, Bach A. et al. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 2012; 97: 2706-2713
• 20 Epstein S, McEachern R, Khot R. et al. Papillary thyroid carcinoma recurrence: Low yield of neck ultrasound with an undetectable serum thyroglobulin level. J Ultras Med 2018; 37: 2325-2331
• 21 Verburg FA, Mäder U, Giovanella L. et al. Low or undetectable basal thyroglobulin levels obviate the need for neck ultrasound in differentiated thyroid cancer patients after total thyroidectomy and 131I ablation. Thyroid 2018; 28: 722-728
• 22 Rosario PW, Mourão GF, Calsolari MR. Repeat ultrasonography in the first years after therapy with radioiodine is not necessary in most patients with papillary thyroid carcinoma when postoperative ultrasonography is negative: A reduction of costs and false-positives. Eur Thyroid J 2019; 8: 41-45
• 23 Lamartina L, Grani G, Durante C. et al. Follow-up of differenciated thyroid cancer – what should (and what should not) be done. Nature Reviews. Endocrinology 2018; 14: 538-551
• 24 Leenhardt L, Erdogan MF, Hegedus L. et al. European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013; 2: 147-155